Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Brainstorm Cell Therapeutics Inc. (BCLI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.3300-0.1500 (-4.31%)
At close: 04:00PM EST
3.0700 -0.26 (-7.81%)
After hours: 06:17PM EST
Advertisement
Full screen
Loading interactive chart...
  • PR Newswire

    BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn® at the International Symposium on ALS/MND

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that biomarker data on NurOwn® will be presented at the 32nd International Symposium on ALS/MND, to be held virtually 7-10 December 2021. The presentation "NurOwn targets multiple disease pathways in ALS Phase 3 Trial" will be delivered by Robert Brown, M.D., Director of the Program in Neurotherapeutics at the University of Massachusetts Medical School, and

  • PR Newswire

    BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium. The presentation, which will be delivered Tomorrow by Dr. Jonathan Katz, a co-principal investigator on the trial and Chair of the Neurology Department and Director of the Forbes Norris ALS Clinic at the California Pacific Medical Center, showed th

  • Zacks Small Cap Research

    BCLI: Biomarkers Predict Response in ALS Phase 3 Trial…

    By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update New Biomarker Data from Phase 3 ALS Trial On October 6, 2021, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced the presentation of an abstract containing new data from the Phase 3 trial in amyotrophic lateral sclerosis (ALS) showing that changes in specific biomarkers were correlated with the primary

Advertisement
Advertisement